Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity RatioInvested CapitalReturn on AssetsReturn on Capital Employed

Cardiol Therapeutics (CRDL) Equity Ratio (2020 - 2025)

Cardiol Therapeutics filings provide 3 years of Equity Ratio readings, the most recent being 0.84 for Q4 2022.

  • On a quarterly basis, Equity Ratio fell 3.0% to 0.84 in Q4 2022 year-over-year; TTM through Dec 2022 was 0.84, a 3.0% decrease, with the full-year FY2022 number at 0.84, down 3.0% from a year prior.
  • Equity Ratio hit 0.84 in Q4 2022 for Cardiol Therapeutics, down from 0.87 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.87 in Q4 2021 to a low of 0.83 in Q4 2020.
  • Median Equity Ratio over the past 3 years was 0.84 (2022), compared with a mean of 0.85.
  • Biggest five-year swings in Equity Ratio: grew 3.9% in 2021 and later decreased 3.0% in 2022.
  • Cardiol Therapeutics' Equity Ratio stood at 0.83 in 2020, then increased by 3.9% to 0.87 in 2021, then decreased by 3.0% to 0.84 in 2022.
  • The last three reported values for Equity Ratio were 0.84 (Q4 2022), 0.87 (Q4 2021), and 0.83 (Q4 2020) per Business Quant data.